Anne Dejean-Assémat, is awarded the Inserm Grand Prix for 2014
26.11.2014 - Communiqué
The Inserm Grand Prix is awarded to Anne Dejean-Assémat, director of Inserm/Institut Pasteur Joint Unit 993 “Nuclear Organization and Oncogenesis,” for her entire body of research on the molecular and cellular mechanisms involved in the development of human cancers. ...
Lung cancer diagnosed before it is detected by imaging
31.10.2014 - Communiqué
A team of researchers from Inserm led by Paul Hofman (Inserm Unit 1081/University of Nice) has just made a significant advance in the area of early diagnosis of invasive cancers. ...
Colon cancer: Two genetic alterations that generate metastases
09.10.2014 - Communiqué
With approximately 42,000 estimated new cases in France in 2012, colon cancer is, for both sexes combined, the third most common type of cancer, and the second most common cause of cancer deaths after lung cancer. ...
New resistance mechanisms to melanoma targeted therapies : contribution of the translation of RNAs into proteins
28.07.2014 - Communiqué
French investigators have discovered new resistance mechanisms to targeted therapies used for less than three years in the treatment of melanoma. This discovery enables us not only to better understand why these treatments become ineffective but also to reveal new avenues for ...
Radiotherapy ‘flashes’ to reduce side effects
21.07.2014 - Communiqué
Treating hard and fast seems to be a good way to limit the side effects of radiotherapy. This is the discovery made by researchers at the Curie Institute, Inserm and the Vaud University Hospital, published in Science Translational Medicine on 16 July. Radiotherapy ...
Cancer: life two years after diagnosis
10.06.2014 - Communiqué
(Français) L’Institut national du cancer (INCa) et l’Inserm présentent, lors d’un colloque de restitution le 10 juin, les résultats d’une enquête de grande envergure interrogeant 4349 personnes atteintes d’un cancer deux ans après le diagnostic. Appelée VICAN2 pour « Vie après le ...